These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 16635071

  • 1. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ.
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL, Church JA, Peter HH, Sleasman JW, Melamed I, Stein MR, Bichler J, IgPro10 in PID Study group.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):272-8. PubMed ID: 19491015
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
    van der Meer JW, van Beem RT, Robak T, Deptala A, Strengers PF.
    Vox Sang; 2011 Aug 28; 101(2):138-46. PubMed ID: 21749402
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.
    Bleasel K, Heddle R, Hissaria P, Stirling R, Stone C, Maher D.
    Intern Med J; 2012 Mar 28; 42(3):252-9. PubMed ID: 22212346
    [Abstract] [Full Text] [Related]

  • 5. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W, Butterweck HA, Auer W, Muchitsch EM, Weber A, Liu SL, Wah PS, Schwarz HP.
    Vox Sang; 2007 Jan 28; 92(1):42-55. PubMed ID: 17181590
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
    Garbett ND, Currie DC, Cole PJ.
    Clin Exp Immunol; 1989 Apr 28; 76(1):1-7. PubMed ID: 2500273
    [Abstract] [Full Text] [Related]

  • 7. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G, Chernyshova L, Kostyuchenko L, Lange A, Nyul Z, Derfalvi B, Musial J, Bellon A, Kappler M, Sadoun A, Bernatowska E.
    J Clin Immunol; 2017 Aug 28; 37(6):539-547. PubMed ID: 28711959
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, Belohradsky BH, Wahn V, Neufang-Hüber J, Zenker O, Grimbacher B.
    Clin Immunol; 2011 Oct 28; 141(1):90-102. PubMed ID: 21705277
    [Abstract] [Full Text] [Related]

  • 9. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
    Matamoros N, De Gracia J, Hernández F, Pons J, Alvarez A, Jiménez V.
    Int Immunopharmacol; 2005 Mar 28; 5(3):619-26. PubMed ID: 15683857
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
    Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, Gupta S, Smits W, Pituch-Noworolska A, Strach M, Pulka G, Ochs HD, Moy JN.
    Eur J Pharm Sci; 2018 Jun 15; 118():80-86. PubMed ID: 29522908
    [Abstract] [Full Text] [Related]

  • 12. Survival of antigen-specific antibody following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases.
    Fischer SH, Ochs HD, Wedgwood RJ, Skvaril F, Morell A, Hill HR, Schiffmann G, Corey L.
    Monogr Allergy; 1988 Jun 15; 23():225-35. PubMed ID: 3386642
    [Abstract] [Full Text] [Related]

  • 13. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
    Aghamohammadi A, Farhoudi A, Nikzad M, Moin M, Pourpak Z, Rezaei N, Gharagozlou M, Movahedi M, Atarod L, Afshar AA, Bazargan N, Hosseinpoor AR.
    Ann Allergy Asthma Immunol; 2004 Jan 15; 92(1):60-4. PubMed ID: 14756466
    [Abstract] [Full Text] [Related]

  • 14. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J, Lokaj J, Stikarovská D, Mayer J, Thon V, Eibl MM.
    Vnitr Lek; 1995 Nov 15; 41(11):759-63. PubMed ID: 8553594
    [Abstract] [Full Text] [Related]

  • 15. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A, Bauer M, Kremer S.
    Pharmacoepidemiol Drug Saf; 2007 Sep 15; 16(9):1038-47. PubMed ID: 17636556
    [Abstract] [Full Text] [Related]

  • 16. [Anaphylactic shock reaction following intravenous administration of 7S immunoglobulin in patients with hypogammaglobulinemia, especially in children with acute lymphoblastic leukemia (ALL)].
    Manzke H, Seifert J.
    Klin Padiatr; 1987 Sep 15; 199(4):274-8. PubMed ID: 3116320
    [Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB, Hanna K, IGIV-C in ITP Study Group.
    Am J Hematol; 2007 Mar 15; 82(3):192-8. PubMed ID: 17109385
    [Abstract] [Full Text] [Related]

  • 18. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF, Brion JP, Malphettes M, Durieu I, Gardembas M, Schleinitz N, Hoarau C, Lazaro E, Puget S.
    Rev Med Interne; 2017 Sep 15; 38(9):578-584. PubMed ID: 28683953
    [Abstract] [Full Text] [Related]

  • 19. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.
    Hopkins RJ, Kramer WG, Blackwelder WC, Ashtekar M, Hague L, Winker-La Roche SD, Berezuk G, Smith D, Leese PT.
    Clin Infect Dis; 2004 Sep 15; 39(6):759-66. PubMed ID: 15472804
    [Abstract] [Full Text] [Related]

  • 20. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.
    Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, Wedgwood RJ.
    J Lab Clin Med; 1988 Nov 15; 112(5):634-40. PubMed ID: 3183495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.